Abiraterone disables an enzyme that produces testosterone and other hormones that encourage tumour growth.
In a study of 8 men, in 5 men, the tumours shrank, levels of prostate-specific antigen in the blood fell 30% in most of the 8 men.
If a future study is successfull,Abiraterone should be avaible in about two years time.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment